

**Chammas & Marcheteau advises Osivax
in its €10 million funding round (Biotechnology)**

Chammas & Marcheteau advised Osivax in its €10 million Series B financing round led by a new incoming investor - the Japanese company Meiji Seika Pharma, followed by two family offices and historical investors of the company.

Founded in 2017, Osivax is a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses.

This new financing will enable the biotech company to accelerate preclinical and clinical development of its broad-spectrum influenza vaccine candidates.

Jérôme Chapron, partner at **Chammas & Marcheteau**, was Osivax's advisor.

About Chammas & Marcheteau

Chammas & Marcheteau is a Paris-based independent law firm that advises companies, investment funds and entrepreneurs on their transactions and development strategies in France and abroad. With more than 60 specialists in business law, including 16 partners, the Firm offers its clients expertise in Private Equity, Mergers & Acquisitions, Funds and Financial Services, Corporate, Restructuring and Turnaround, Tax, Intellectual Property and Information Technology, Employment Law, Real Estate and Business Litigation.